Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04885530 · ClinicalTrials.gov registry record · Phase 3
ACTIV-6: COVID-19 Study of Repurposed Medications
A Phase 3 study, sponsored by Susanna Naggie, MD.
- Completed
- Registry status
- Phase 3
- Development phase
- 10,956
- Enrollment target
NCT04885530: Completed Phase 3 study, sponsored by Susanna Naggie, MD.
NCT04885530 is a Phase 3 study that has completed, run by Susanna Naggie, MD. The registered enrollment target is 10,956 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1321% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04885530, a Phase 3 study, has completed, sponsored by Susanna Naggie, MD.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 10,956 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. They will self-report any new or worsening symptoms or medical events they may experience while taking study drug or placebo. This study is intended to be all remote with no in person visits, unless the study team feels it is in the best interest of a participant to see them in person. Prior and current drug arms are listed on clinicaltrials.gov and will be updated with the activation of any new drug arms. Each study arm will also have its own clinicaltrials.gov entry and will include "Pro00107921" in the Unique Protocol ID. Pro00107921\_A - Arm D (Ivermectin 400) - NCT05736861; Pro00107921\_B - Arm B (Fluvoxamine) - NCT05890586; Pro00107921\_C - Arm C (Fluticasone) - NCT05736874; Pro00107921\_D - Arm D (Ivermectin 600) - NCT05894538; Pro00107921\_E - Arm E (Fluvoxamine 100) - NCT05894564; Pro00107921\_F - Arm F (Montelukast) - NCT05894577; Pro00107921\_G - Arm G (Metformin) - NCT06042855.
Primary Outcome
Total number of participants randomized within each Appendix will be reported. Appendix-specific outcome measure data will be reported under the associated NCT ID.
Interventions
- OTHER Placebo
- DRUG Ivermectin
- DRUG Fluticasone
- DRUG Montelukast
- DRUG Fluvoxamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,956 participants |
| Start Date | 2021-06-08 |
| Est. Completion | 2024-04-29 |
| Phase | Phase 3 |
What the finished NCT04885530 record still lists
NCT04885530 is an interventional study that assigns participants to a tested intervention. Its 10,956 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1321% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT04885530 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04885530 about?
NCT04885530 is a clinical study titled "ACTIV-6: COVID-19 Study of Repurposed Medications". The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. They will self-report any new or worsening symptoms or med...
What is the current status of trial NCT04885530?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 10,956 participants. The study started on 2021-06-08. Estimated completion is 2024-04-29.
What interventions are being tested in trial NCT04885530?
The interventions under investigation include: Placebo (OTHER), Ivermectin (DRUG), Fluticasone (DRUG), Montelukast (DRUG), Fluvoxamine (DRUG).
Who is sponsoring clinical trial NCT04885530?
This trial is sponsored by Susanna Naggie, MD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04885530's enrollment target sits among peer trials
10,956 25th of 2000 higher than 1,976 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06531824 · 11,000 participants · Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
- NCT07136012 · 11,000 participants · Phase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
- NCT07181109 · 11,000 participants · Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
- NCT06736951 · 10,890 participants · NA
Modifying the Inpatient Environment to Reduce Delirium in Older Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI